Scheme 2. Chloro Merrifield Resin Conversiona
a NaN3 (3 equiv), DMF, 24 h, rt.
Figure 1. Linker concept.
Intermediate 4 was loaded onto the Merrifield azide
resin 5 (Scheme 3) via CuAAC13 to render CHO-BTL
resin. This reaction was carried out in ACN, ascorbate of
sodium, 2,6-lutidine, DIEA, and DMF as solvent for 6 h at
room temperature. If only catalytic amounts of CuBr are
used, reaction times should increase. The progress of
CuAAC was monitored using IR spectroscopy, through
the loss of the azide band and the appearance of new
vibrational modes at 1673 cmꢀ1 and 1546 cmꢀ1, indicative
of the carbonyl group and the alkene of the triazol moiety,
respectively.
The copper-catalyzed azideꢀalkyne cycloaddition
(CuAAC) has been extensively used in SPS to obtain cyclic
peptides,5 triazolyl aminoacyl (peptidyl) penicillins,6 and
aldehyde-functionalized resins.7 For efficient and stable
coupling of the linker to a solid support, this reaction
requires an alkyne- and an azide-functionalized resin asthe
solid support.8
First, 5-ethynyl-2,4-dimethoxybenzaldehyde (4) was
synthesized from commercially available 2,4-dimethoxyben-
zaldehyde (1) (Scheme 1), which was iodated with iodine
monochloride at C5 of 1.9 The alkyne moiety was intro-
duced by a Sonogashira coupling reaction,10 exchanging the
iodine atom by TMSA, to obtain 3. Subsequent deprotec-
tion gave the intermediate 4 in an overall yield of 28%.
To generate the Merrifield azide resin 5, ClꢀMerrifield
resin (0.7 mmol Cl/g) was reacted with sodium azide in DMF
(Scheme 2) following a previous reported method with slight
modifications (conversion was carried at room temperature
rather than at 60 °C).11 The reduction/ninhydrin test was
used to monitor the incorporation of azide function on the
resin.12 Treatment with the standard PPh3, ninhydrin, pyr-
idine, and phenol solutions followed by warming gave a
positive result (solution turned dark purple). This step was
also monitored using IR spectroscopy to corroborate the
The OH-BTL resin was finally obtained by reducing
CHO-BTL resin using NaBH4 in THF/MeOH.
The OH-BTL resin was characterized by IR spectro-
metry, and its stability was evaluated under standard acid
conditions by treatment with the cleavage cocktail [TFA/
TIS/H2O (95:2.5:2.5)] during 1, 2, 3, and 24 h. Filtrates
after each treatment were analyzed by HPLC and HPLC-
MS. No cleavage from the resin was detected. Also, no
change in the IR spectra of any of the residual resins was
detected. Once the stability of the linker anchored to the
resin was validated, the scope and limitations of this new
resin in comparison with a standard Wang resin were
examined. Thus, three model peptides were synthesized
by the Fmoc/tBu strategy: Leu-enkephalin (H-Tyr-Gly-
Gly-Phe-Leu-OH) 6, RGD pentapetide (H-Arg-Gly-Asp-
Gly-Trp-OH) 7, and Indolicidin (H-Ile-Leu-Pro-Trp-Lys-
Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-OH) 8.
successful conversion of 5 (νN = 2092 cmꢀ1).
3
The first Fmoc-amino acid was incorporated into both
resins using the symmetrical anhydride in the presence of
catalytic amounts of DMAP, while DIPCDI-OxymaPure
was used for the rest of the residues.14 The symmetrical
anhydride was a satisfactory method for introducing
the first amino acid on the OH-BTL resin (Table 1),
as demonstrated by means of UV analysis of the
Scheme 1. Synthesis of 5-Ethynyl-2,4-dimethoxy-
benzaldehyde (4)a
(7) Lober, S.; Rodiguez-Loaiza, P.; Gmeiner, P. Org. Lett. 2003, 5,
1753.
(8) Azide resins, which are prepared in a straightforward manner
from commercially available chloromethyl or amino resins, are more
convenient that alkyne resins for this purpose.
(9) Meng, C. Q.; Ni, L.; Worsencroft, K. J.; J. Ye, Z.; Weingarten,
M. D.; Simpson, J. E.; Skudlarek, J. W.; Marino, E. M.; Suen, K.;
Kunsch, C.; Souder, A.; Howard, R. B. J. Med. Chem. 2007, 50, 1304.
(10) Esser, B.; Bandyopadhyay, A.; Rominger, F.; Gleiter, R.
Chem.;Eur. J. 2009, 15, 3368.
(11) (a) Kumar, S. J. Phys. Chem. 2010, 114, 11395. (b) Riente, P.
Org. Lett. 2012, 14, 3668. Janout, V.; Jing, B.; Regen, S. L. Bioconjugate
Chem. 2002, 13 (2), 356.
a (i) ICl (1.2 equiv), MeOH, 3 h, rt; (ii) Pd(PPh3)4 (0.03 equiv), CuI
(0.005 equiv), Piperidine (1.9 equiv), TMSA (1.2 equiv), THF, 1 h, rt; (iii)
K2CO3 (2 equiv), DCM/MeOH (9:1), 1 h, rt.
(12) Punna, S.; Finn, M. G. Synlett 2004, 1, 99.
(13) Turner, R., A.; Oliver, A., G.; Lokey, R., S. Org. Lett. 2007, 9,
5011.
(5) Metaferia, B. B.; Rittler, M.; Gheeya, J. S.; Lee, A.; Hempel, H.;
Plaza, A.; Stetler-Stevenson, G.; Bewley, C. A.; Khan, J. Bioorg. Med.
Chem. Lett. 2010, 20, 7337.
ꢁ
(6) Cornier, P. G.; Boggain, D. B.; Mata, E. G. Tetrahedron Lett.
2012, 53, 632.
(14) Subiros-Funosa, R.; Prohens, R.; Barbas, R.; El-Faham, A.;
Albericio, F. Chem.;Eur. J. 2009, 15, 9394.
Org. Lett., Vol. 15, No. 2, 2013
247